BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Model scores of the 29,894 trials active now.

Model score 35% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-05-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: small celllung cancercell lungnon smallstage
  Phrases that lowered it: aminotransferasemlmgvaccinebreast
• Sponsor's past termination rate: 100% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 94.0% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports with a death: 21.1% (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 9909 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer NCT00970684 · started 2009 · scored riskier than 95% of active trials completed
• Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer NCT00541099 · started 2008 · scored riskier than 58% of active trials completed
• Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer NCT01107626 · started 2010 · scored riskier than 95% of active trials completed
• S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer NCT00946712 · started 2009 · scored riskier than 95% of active trials terminated
• Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer NCT00741988 · started 2008 · scored riskier than 82% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.